Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
复制标题
单纯疱疹病毒糖蛋白治疗复发性生殖器疱疹。
DOI：
10.1093/infdis/157.1.156
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Myers,MG
中科院分区：
文献类型：
--
作者：
Stanberry,LR;Burke,R;Myers,MG
我们利用豚鼠生殖器HSV感染模型研究单纯疱疹病毒（HSV）糖蛋白可能为复发性HSV疾病提供潜在的免疫治疗。在两项实验中，在最初的生殖器疱疹恢复后，58只动物被随机分配接受糖蛋白疫苗或作为对照组。从感染组织培养物中获得的HSV-2糖蛋白混合物和在哺乳动物细胞中通过基因工程制备的HSV-1糖蛋白带D的混合物，都降低了随后疱疹复发的频率（P< 0.05）和严重程度（P< 0.05）。我们的结论是，疱疹病毒病的复发可以通过给予免疫原性病毒蛋白来改变；因此，单纯疱疹病毒糖蛋白可作为控制人类复发性单纯疱疹病毒感染的免疫治疗剂。
We investigated the possibility that herpes simplex virus (HSV) glycoproteins might provide potential immunotherapy for recurrent HSV disease by using the guinea pig model of genital HSV infection. In two experiments, after recovery from initial genital herpes, 58 animals were randomized either to receive a glycoprotein vaccine or to serve as controls. Both a mixture of HSV-2 glycoproteins derived from infected tissue cultures and a mixture of HSV-1 glycoproteins Band D, prepared by genetic engineering in mammalian cells, reduced the frequency (P<.05) and severity (P<.05) of subsequent herpetic recurrences. We conclude that recurrences of established herpesvirus disease may be altered by administering immunogenic viral proteins; thus, HSV glycoproteins may be useful as immunotherapeutic agents for controlling recurrent HSV infection in humans.